Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex32220191231.htm |
| EX-32.1 - EXHIBIT 32.1 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex32120191231.htm |
| EX-31.2 - EXHIBIT 31.2 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex31220191231.htm |
| EX-31.1 - EXHIBIT 31.1 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex31120191231.htm |
| EX-4.8 - EXHIBIT 4.8 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex4820191231.htm |
| 10-K - 10-K - ALPINE IMMUNE SCIENCES, INC. | a10k2019.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-205220) pertaining to the 2012 Stock Incentive Plan of N30 Pharmaceuticals, Inc., 2015 Equity Incentive Plan of Nivalis Therapeutics, Inc. and Employee Stock Purchase Plan of Nivalis Therapeutics, Inc., | |
(2) | Registration Statement (Form S-8 No. 333-211197) pertaining to the Employment Inducement Awards of Nivalis Therapeutics, Inc., | |
(3) | Registration Statement (Post-Effective Amendment No. 1 on Form S-8 to Form S-4 No. 333-218134) pertaining to the Amended and Restated 2015 Stock Plan of Alpine Immune Sciences, Inc., | |
(4) | Registration Statement (Form S-8 No. 333-223965) pertaining to the Amended and Restated 2015 Stock Plan, as amended, and the 2015 Equity Incentive Plan of Alpine Immune Sciences, Inc., | |
(5) | Registration Statement (Form S-8 No. 333-225792) pertaining to the 2018 Equity Incentive Plan of Alpine Immune Sciences, Inc., | |
(6) | Registration Statement (Form S-1 No. 333-230365) and related Prospectus of Alpine Immune Sciences, Inc. for the registration of 6,542,310 shares of its common stock, | |
(7) | Registration Statement (Form S-8 No. 333-230369) pertaining to the 2018 Equity Incentive Plan of Alpine Immune Sciences, Inc., and | |
(8) | Registration Statement (Form S-8 No. 333-230372) pertaining to the Stand-Alone Inducement Stock Option Grant of Alpine Immune Sciences, Inc., | |
of our report dated March 30, 2020, with respect to the consolidated financial statements of Alpine Immune Sciences, Inc., included in this Annual Report (Form 10-K) of Alpine Immune Sciences, Inc. for the year ended December 31, 2019.
/s/ Ernst & Young
Seattle, Washington
March 30, 2020